Showing results (211-220 of 410) with videos related to

Sort By:
Pageof 41
Biochimica Et Biophysica Acta|October 6, 2000
Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5)U Mahlknecht, S Schnittger, O G Ottmann, et al.
Blood|October 1, 1988
Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM)C Carlo-Stella, M Cazzola, A Ganser, et al.
Seminars in Oncology|April 1, 1992
Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugsA Ganser, G Seipelt, M Eder, et al.
Bone Marrow Transplantation|November 1, 1994
Microangiopathic hemolytic anemia and renal impairment following autologous bone marrow transplantation: a case of hemolytic uremic syndrome?B Wassmann, H Martin, S Elsner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1995
Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma--a multicenter phase II studyL Bergmann, T Karakas, G Lautenschlager, et al.
Onkologie|June 1, 1986
Age adapted induction and intensified consolidation therapy in acute myelogenous leukemiaE Kurrle, G Ehninger, M Freund, et al.
Leukemia & Lymphoma|June 1, 1999
Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significanceS Schwartz, A Heinecke, M Zimmermann, et al.
Haematologica|February 27, 2001
Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotypingC Wuchter, R Ratei, G Spahn, et al.
Experimental Hematology|September 1, 1991
Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cellsO G Ottmann, C C Stella, M Eder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphomaE Weidmann, S-Z Kim, A Rost, et al.
Pageof 41